Clinical Trials

The doctors at Hematology/Oncology Clinic have more than 20 years of experience in conducting and treating patients through national clinical trials. Clinical trials are studies that evaluate the effectiveness of drugs or treatment routines. Our goal is to give patients the opportunity to participate in approved and exploratory therapies without long-distance travel. Clinical trials are not available for every condition. Talk to your doctor to discuss your options, or call 225.767.0822 and ask to speak to a member of our research team.

Active Clinical Protocols


Study Number: ACT16105
Sponsor:  SANOFI
Protocol Name:  A Randomized Phase II Trial of SAR439859, a New Serd Compound, Versus Fulvestrant in Patients With HR+, HER2-, Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies.  NCT 04059484


Study Number: NRG-BR003
Sponsor:  NRG Oncology
Protocol Name:  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer  NCT 02488967

Lung-NSCLC Stage III

Study Number: D9108C00001-COAST
Protocol Name:  Phase 2, Open Label, Multi-drug Platfrom Study of Durvalumab Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) NSCLC  NCT 03822351


Study Number: D419BR00008-PREVAIL Registry
Protocol Name:  A Prospective, Non-interventional Study to Assess PD-L1 Expression in the First-line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma  NCT 03788746


Study Number: DB102-02
Sponsor:  Caris / Denovo Biopharma LLC
Protocol Name:  A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™  NCT 03263026

Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Study Number: EAY131 - MATCH
Protocol Name:  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)  NCT 02465060

Rare tumors

Study Number: SWOG 1609 (DART)
Sponsor:  SWOG
Protocol Name:  A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.  NCT 02834013

Follicular Lymphoma

Study Number: GS-US-313-1580
Sponsor:  Gilead Sciences
Protocol Name:  Dose Optimization Study of Idelalisib in Follicular Lymphoma  NCT 02536300


Study Number: HCRN GU17-289
Sponsor:  Hoosier Cancer Research Network
Protocol Name:  Phase 2 Randomized, Open Label Study of HD-IL2 Vs HD-IL2 + Entinostat in Untreated Advanced Renal Cell Carcinoma  NCT 03501381


Study Number: 7902-008
Sponsor:  Merck Sharp & Dohme Corp.
Protocol Name:  Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)  NCT 03976375

Choosing to participate in a clinical trial is an important personal decision.

Our physicians and staff are available to assist you in making that decision.

For more information about the clinical trials available you may call the research office at 225.767.0822 ext. 260.